Drugs / NCX 4251
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04675242 | Dec 2020 → Jun 2021 | blepharitis | Nicox Ophthalmics, Inc. | Completed | Missed primary |
Press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-02-22 | NicOx Inc. | Nicox Granted New Patent for NCX 4251 in Japan nicox.com ↗ |
| 2022-02-08 | NicOx Inc. | Nicox’s Positive FDA Meeting Shows Clear Path for NCX 4251 in Dry Eye nicox.com ↗ |
| 2021-11-30 | NicOx Inc. | Nicox’s Positive Post Hoc Results from NCX 4251 Phase 2b Mississippi Trial Suggest Path Forward in Dry Eye Disease nicox.com ↗ |
| 2021-11-17 | NicOx Inc. | Nicox is Granted Patent for Blepharitis Product Candidate NCX 4251 in Europe nicox.com ↗ |
| 2021-09-24 | NicOx Inc. | Nicox Announces Results from the NCX 4251 Phase 2b Mississippi Blepharitis Trial nicox.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NCX 4251 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04675242 ↗ |